Infliximab
Cold Chain RequiredFDA Approved
Description
Infliximab is a TNF blocker used to reduce inflammation in autoimmune conditions. It is a chimeric monoclonal antibody that binds to human tumor necrosis factor alpha (TNFα), preventing it from binding to its receptors.
Indications & Therapeutic Use
Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, Ankylosing Spondylitis, Psoriatic Arthritis, Plaque Psoriasis
Linked Diseases:
Global Availability (5 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Infliximab
| Generic Name | Infliximab |
| Brands | 1 brand available |
| Active Ingredient | Infliximab |
| Drug Class | Rheumatoid Arthritis |
| Manufacturer | Janssen Biotech |
| Dosage Forms | Intravenous infusion |
| Medical Code | L04AB02 |
| Orphan Status | No |
| Cold Chain | Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved |
| Clinical Trial | NCT00026270 |
| Countries | 5 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations6 Validated Nodes